Complete responses to odronextamab in two patients with diffuse large B-cell lymphoma refractory to chimeric antigen receptor T-cell therapy

被引：3

作者：

Weinstock, Matt ^{[1
]}

Elavalakanar, Pavania ^{[1
]}

Bright, Susan ^{[1
]}

Ambati, Srikanth R. ^{[2
]}

Brouwer-Visser, Jurriaan ^{[2
]}

Pourpe, Stephane ^{[2
]}

Fiaschi, Nathalie ^{[2
]}

Jankovic, Vladimir ^{[2
]}

Thurston, Gavin ^{[2
]}

Deering, Raquel P. ^{[2
]}

Chaudhry, Aafia ^{[2
]}

Joyce, Robin ^{[1
]}

Arnason, Jon ^{[1
]}

机构：

[1] Beth Israel Deaconess Med Ctr, Hematol Oncol, Boston, MA 02215 USA

[2] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2022年 / 199卷 / 03期

关键词：

bispecific antibodies; cellular therapies; clinical trials; non-Hodgkin lymphoma; tumour immunotherapy;

D O I：

10.1111/bjh.18383

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Outcomes remain poor for patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). While chimeric antigen receptor (CAR) T-cell therapy has revolutionised treatment, a significant proportion of patients relapse or fail to respond. Odronextamab is a CD20 x CD3 bispecific antibody that has demonstrated durable responses and a manageable safety profile in patients with R/R B-NHL in a first-in-human trial (NCT02290951). Here, we document two patients with diffuse large B-cell lymphoma refractory to CART-cell therapy. Both achieved complete responses that remain ongoing for >= 2 years following odronextamab. Neither patient experienced Grade >= 3 cytokine release syndrome or Grade >= 3 neurological adverse events during treatment.

引用

页码：366 / 370

页数：5

共 50 条

[31] Cytomegalovirus impact in b-cell lymphoma patients treated with chimeric antigen receptor t-cell therapy
Marquez-Algaba, E.
Pernas, B.
Esperalba, J.
Los-Arcos, I.
Carpio, C.
Iacoboni, G.
Barba, P.
Ruiz-Camps, I.
BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 134 - 134
[32] Brain FDG-PET findings in chimeric antigen receptor T-cell therapy neurotoxicity for diffuse large B-cell lymphoma
Morbelli, Silvia
Gambella, Massimiliano
Raiola, Anna Maria
Ghiggi, Chiara
Bauckneht, Matteo
Raimondo, Tania Di
Lapucci, Caterina
Sambuceti, Gianmario
Inglese, Matilde
Angelucci, Emanuele
JOURNAL OF NEUROIMAGING, 2023, 33 (05) : 825 - 836
[33] Perceptions of Community Hematologists/Oncologists on Barriers to Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Diffuse Large B-Cell Lymphoma
Gajra, Ajeet
Sweat, Richard
Jeune-Smith, Yolaine
Kish, Jonathan K.
Feinberg, Bruce A.
BLOOD, 2019, 134
[34] Perceptions of community hematologists/oncologists on barriers to chimeric antigen receptor T-cell therapy for the treatment of diffuse large B-cell lymphoma
Gajra, Ajeet
Jeune-Smith, Yolaine
Kish, Jonathan
Yeh, Ting-Chun
Hime, Skyler
Feinberg, Bruce A.
IMMUNOTHERAPY, 2020, 12 (10) : 725 - 732
[35] Efficacy and safety of chimeric antigen receptor T cell therapy combined with zanubrutinib in the treatment of relapsed/refractory diffuse large B-cell lymphoma
Wang, Langqi
Yue, Chunyan
Zhou, Xuan
Yang, Jilong
Jin, Bo
Wang, Bo
Huang, Minhong
Chen, Huifang
Zhou, Lijuan
Tu, Sanfang
Li, Yuhua
CHINESE MEDICAL JOURNAL, 2025, 138 (06) : 748 - 750
[36] Prognostic differences of refractory/relapsed nodal and extranodal diffuse large B-cell lymphoma in the chimeric antigen receptor T cell therapy era
Song, Zhiqiang
Xu, Lili
Tang, Gusheng
Gao, Lei
Wang, Libing
Ni, Xiong
Chen, Li
Chen, Jie
Wang, Tao
Feng, Dongge
Yu, Xuejun
Yang, Jianmin
Wang, Yang
CLINICA CHIMICA ACTA, 2022, 532 : 72 - 78
[37] Relapsed or refractory large B-cell lymphoma after chimeric antigen receptor T-cell therapy: Current challenges and therapeutic options
Toro-Mijares, Raul Del
Oluwole, Olalekan
Jayani, Reena V.
Kassim, Adetola A.
Savani, Bipin N.
Dholaria, Bhagirathbhai
BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 (01) : 15 - 24
[38] Outcomes after chimeric antigen receptor T-cell therapy across large B-cell lymphoma subtypes
Bourlon, Christianne
Roddie, Claire
Menne, Tobias
Norman, Jane
O'Reilly, Maeve
Gibb, Adam
Besley, Caroline
Chaganti, Sridhar
Arias, Carlos Gonzalez
Jones, Ceri
Dikair, Abdalla
Allen, Sharon
Seymour, Frances
Osborne, Wendy
Mathew, Amrith
Townsend, William
Patten, Piers E. M.
Thoulouli, Eleni
Abdulgawad, Ahmed
Lugthart, Sanne
Sanderson, Robin
Kirkwood, Amy A.
Kuhnl, Andrea
HAEMATOLOGICA, 2024, 109 (08) : 2716 - 2720
[39] Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma
Strati, Paolo
Ahmed, Sairah
Furqan, Fateeha
Fayad, Luis E.
Lee, Hun J.
Iyer, Swaminathan P.
Nair, Ranjit
Nastoupil, Loretta J.
Parmar, Simrit
Rodriguez, Maria A.
Samaniego, Felipe
Steiner, Raphael E.
Wang, Michael
Pinnix, Chelsea C.
Horowitz, Sandra B.
Feng, Lei
Sun, Ryan
Claussen, Catherine M.
Hawkins, Misha C.
Johnson, Nicole A.
Singh, Prachee
Mistry, Haleigh
Johncy, Swapna
Adkins, Sherry
Kebriaei, Partow
Shpall, Elizabeth J.
Green, Michael R.
Flowers, Christopher R.
Westin, Jason
Neelapu, Sattva S.
BLOOD, 2021, 137 (23) : 3272 - 3276
[40] An assessment model for efficacy of autologous CD19 chimeric antigen receptor T-cell therapy and relapse or refractory diffuse large B-cell lymphoma risk
Xue Bin
Liu Yifan
Zhang Min
Xiao Gangfeng
Luo Xiu
Zhou Lili
Ye Shiguang
Lu Yan
Qian Wenbin
Wang Li
Li Ping
Liang Aibin
中华医学杂志英文版, 2025, 138 (01)

← 1 2 3 4 5 →